Market Overview

Synthetic Biologics Surges 25% Amid Positive Phase 2 Data

Share:

Shares of Synthetic Biologics Inc (NYSE: SYN), a clinical-stage biotechnology company, surged higher by 25 percent at $1.90 early Wednesday morning after the company reported positive topline data from a second Phase 2 clinical trial.

Synthetic Biologics stated that its second Phase 2 clinical trial of its SYN-010 for the treatment of irritable bowel syndrome with constipation has met its primary endpoint.

According to the company's press release, "Topline data from all patients who completed the second Phase 2 clinical trial of SYN-010 showed a statistically significant decrease in methane production (p=0.002) from the beginning of the first Phase 2 study (Study 1 baseline - Day 1) to the end of the second Phase 2 study (12 weeks of treatment - Day 84), thus meeting the study's primary endpoint. There were no serious adverse events observed."

"Meeting the study endpoints and demonstrating positive clinical outcomes in this Phase 2 trial of SYN-010 bring us closer to offering a therapeutic to the millions of people who suffer from IBS-C," said Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. "During the first half of 2016, we anticipate reporting detailed results from this Phase 2 clinical trial and requesting an end of Phase 2 meeting with the FDA. Concurrent with the analysis of the Phase 2 data, we are actively planning the Phase 3 program for SYN-010."

Synthetic Biologics will host a conference call on Wednesday at 8:30 a.m. ET to further discuss the trial.

Posted-In: Irritable Bowel Syndrome Phase 2 Clinical Trial SYN-010Biotech News Health Care Movers General

 

Related Articles (SYN)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

10 Stocks Moving In Wednesday's Pre-Market Session

REIT ETFs Still Offering Consistent Dividend Growth